Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Ga-68-DOTA-TATE
- drug: F-18 FDG
- device: Positron Emission Tomography / Computed Tomography (PET/CT) Scan
- device: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
Eligibility
INCLUSION CRITERIA
- Cancer diagnosis
- Capable of complying with study procedures
- Able to remain still for duration of imaging procedure (approximately 90 minutes
total)
- Written informed consent
EXCLUSION CRITERIA
- Pregnant or nursing
- Metallic implants
- Impaired renal function
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.